We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H2 2018

Published: September 2018
Pages: 70
Code: CC9FB5D1525894CC51425FA95F78E907
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 3,500.00
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 3 and 4 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory and Toxicology which include indications Insomnia, Narcolepsy, Sleep Disorders, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Obstructive Sleep Apnea, Opioid Induced Side Effects and Parkinson's Disease.
The latest report Orexin Receptor Type 2- Pipeline Review, H2 2018, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
  • - The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • - The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
  • - The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • - The report summarizes all the dormant and discontinued pipeline projects
  • - The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics

Companies Mentioned

Actelion Pharmaceuticals Ltd
Eisai Co Ltd
Evotec AG
Heptares Therapeutics Ltd
Idorsia Pharmaceutical Ltd
Johnson & Johnson
Merck & Co Inc
OptiNose US Inc
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Add to basket
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development
  • Actelion Pharmaceuticals Ltd
  • Eisai Co Ltd
  • Evotec AG
  • Heptares Therapeutics Ltd
  • Idorsia Pharmaceutical Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • OptiNose US Inc
  • Takeda Pharmaceutical Co Ltd
  • Yangtze River Pharmaceutical Group
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles
  • HTL-6641 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lemborexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MK-8133 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nemorexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OPN-021 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • seltorexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • suvorexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-925 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YNT-185 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 19, 2018: Eisai annonce presentation on lemborexant at (AAIC) 2018
  • Jul 02, 2018: Eisai to Give Oral Presentation on Results of Phase III Head-to-head Clinical Study of Lemborexant in Insomnia Disorder at 43rd Annual Meeting of the Japan Society of Sleep Research
  • Jun 11, 2018: Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia
  • Jun 05, 2018: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
  • May 22, 2018: Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant to be Presented at the 32nd Annual SLEEP Meeting
  • Mar 07, 2018: Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
  • Dec 21, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder
  • Dec 07, 2017: Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting
  • Dec 06, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
  • Oct 31, 2017: Eisai to Present Latest Data on lemborexant at 10th Clinical Trials on Alzheimer's Disease
  • Sep 05, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
  • Jul 28, 2017: ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia
  • Oct 28, 2016: Eisai To Initiate Phase II Clinical Study Of Dual Orexin Receptor Antagonist Lemborexant In Patients With Irregular Sleep-Wake Rhythm Disorder And Dementia
  • Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia
  • Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
  • List of Tables
  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indication, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by Actelion Pharmaceuticals Ltd, H2 2018
  • Pipeline by Eisai Co Ltd, H2 2018
  • Pipeline by Evotec AG, H2 2018
  • Pipeline by Heptares Therapeutics Ltd, H2 2018
  • Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
  • Pipeline by Johnson & Johnson, H2 2018
  • Pipeline by Merck & Co Inc, H2 2018
  • Pipeline by OptiNose US Inc, H2 2018
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
  • Pipeline by Yangtze River Pharmaceutical Group, H2 2018
  • Dormant Projects, H2 2018
  • Discontinued Products, H2 2018
  • List of Figures
  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

Keywords
;